| 98.75 Real-Time Quote |  +1.50 / +1.54%Today’s Change | 81.28 Today|||52-Week Range 116.45 | +7.65% Year-to-Date |
| Patent Challenge from Perrigo - Analyst Blog May 31 / Zacks.com |
| Previous close | 97.25 |
| Today’s open | 97.45 |
| Day’s range | 96.81 - 98.66 |
| Volume | 1,140,477 |
| Average volume (3 months) | 1,992,055 |
| Market cap | $28.8B |
| Dividend yield | 0.20% |
| Earnings growth (last year) | +18.94% |
| Earnings growth (this year) | +14.62% |
| Earnings growth (next 5 years) | +14.00% |
| Revenue growth (last year) | +8.58% |
| P/E ratio | 26.4 |
| Price/Sales | 4.76 |
| Price/Book | 5.00 |
| Today’s change | Today’s % change | |
|---|---|---|
| VRXValeant Pharmaceutic... | +0.34 | +0.40% |
| SHPGShire PLC | -0.30 | -0.31% |
| ALXNAlexion Pharmaceutic... | +1.02 | +1.12% |
| VRTXVertex Pharmaceutica... | +1.05 | +1.36% |
| Next reporting date | July 31, 2013 |
| EPS forecast (this quarter) | $1.20 |
| Annual revenue (last year) | $5.8B |
| Annual profit (last year) | $1.1B |
| Net profit margin | 18.92% |
Sector Health Technology |
Industry Pharmaceuticals: Other |
Chairman, President & Chief Executive Officer David E. I. Pyott, MBA |
Chief Financial Officer & EVP-Business Development Jeffrey L. Edwards |
Corporate headquarters Irvine, California |
.
